Lupin receives approval from USFDA for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body
These patches can be used in settings where patients need close vital signs monitoring, including cardiac rhythm.
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
Subscribe To Our Newsletter & Stay Updated